Big things are happening recently with Creso Pharma (ASX: CPH) (OTC: COPHF) (FRA: 1X8), most notably the closing of the company’s acquisition of Canadian psychedelics firm Halucenex Life Sciences and the major announcement that saw Canopy Growth (TSX: WEED) (NASDAQ: CGC) (FRA: 11L1) founder and former CEO Bruce Linton confirm that he will be joining The HighBrid Lab following the completion of the Creso Pharma Red Light Holland (CSE: TRIP) (OTC: TRUFF) (FRA: 4YX) merger.
In even bigger news, on Monday, Creso announced that its wholly-owned psychedelics subsidiary, Halucenex secured the highly sought-after Controlled Drugs and Substances Dealer’s Licence from Health Canada. As one of the few companies worldwide with a Dealer’s Licence, Halucenex can now possess, sell, transport and conduct R&D on a range of psychedelics, such as psilocybin, ketamine, LSD and MDMA.
This news is a milestone achievement for Halucenex as the Creso Pharma-owned psychedelics firm can now move forward with its planned phase II clinical trial, which will seek to test the efficacy of psilocybin on treatment-resistant post-traumatic stress disorder (PTSD).
“We are very eager to begin working with Halucenex ahead of the creation of The HighBrid Lab and explore opportunities which will increase the uptake and availability of psychedelics as an evolutionary treatment route to existing therapies. As the mental health crisis continues to unfold, the need for effective treatments is becoming much clearer. The potential and requirements for new treatment pathways is also becoming widely recognised by regulatory bodies, governments and large pharmaceutical companies – all of which provide us with a number of avenues as we embark on test work, R&D and commercialisation,” commented incoming The HighBrid Lab Chairman Bruce Linton.
Stay tuned for further updates on Creso Pharma, Halucenex and the soon-to-be The HighBrid Lab.
For more information on these companies, please check out the research materials below:
- Click Here to Read the Creso Pharma + Red Light Holland = The HighBrid Lab Investor Presentation
- Click here to Read the Halucenex Life Sciences Investor Presentation
Learn more about Creso Pharma: Website | IR Website | Investor Deck | CPH Chart
Trending: Massive Win for Creso Pharma’s Psychedelics Subsidiary as Halucenex Secures Coveted Health Canada Dealer’s Licence
- Creso Pharma’s Halucenex Continues to Make Strong Progress in Psychedelics Industry Ahead of Phase II Clinical Trials
- Creso Pharma Closes Halucenex Psychedelics Acquisition, Bruce Linton to Become Chairman of The HighBrid Lab
- Creso Pharma to Merge With Psychedelics Leader Red Light Holland, Combined Company Set to Become a Cannabis and Psychedelics Industry Juggernaut
With U.S. Pot Stocks the Hot Theme of 2021, Here’s Why Red White & Bloom Could Be One of the Cannabis Sector’s Top Performers
Follow TCI on Social Media: Facebook | Instagram | Twitter | LinkedIn | Investor Group
Follow Psychedelic Profits on Social Media: Facebook | Twitter | LinkedIn | Investor Group
Did you enjoy this article? If so, sign up for our Email Newsletter below to start receiving our weekly recap of the week’s best articles.
Get Your Copy of The Ultimate Cannabis Investing Guide
Join the Discussion in the TCI Investor Group
Creso Pharma is a paid client of The Cannabis Investor. The Cannabis Investor does not hold a position in CPH.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
Featured ArticlesCannabis Stock NewsCannabis Industry ArticlesTechnical Analysis ArticlesWatch Cannabis Stock Videos